The Impact of Plastic Chemicals on the Transcriptomic Profile of MCF-7 Breast Cancer Cells - Top-Institutions - MDSpire

The Impact of Plastic Chemicals on the Transcriptomic Profile of MCF-7 Breast Cancer Cells

  • By

  • Geronimo Matteo

  • David C. Eickmeyer

  • Lauren M. Bradford

  • Matthew J. Meier

  • Andrew Williams

  • Tara Barton-Maclaren

  • J. Christopher Corton

  • Carole L. Yauk

  • Ella Atlas

  • April 20, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Harvard T.H. Chan School of Public Health
    Harvard T.H. Chan School of Public Health

    Boston, MA

    Key Differentiators

    • Environmental Health
    • Epidemiology
    • Molecular Toxicology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Breast Cancer Research
    • Molecular Oncology
    • Endocrine Disruption

  • #3

    National Institute of Environmental Health Sciences (NIEHS)
    National Institute of Environmental Health Sciences (NIEHS)

    Research Triangle Park, NC

    Key Differentiators

    • Environmental Toxicology
    • Endocrine Disruption
    • Molecular Biology

  • #4

    Johns Hopkins Bloomberg School of Public Health
    Johns Hopkins Bloomberg School of Public Health

    Baltimore, MD

    Key Differentiators

    • Environmental Health Sciences
    • Cancer Epidemiology
    • Molecular Toxicology

Original Source(s)

The Impact of Plastic Chemicals on the Transcriptomic Profile of MCF-7 Breast Cancer Cells

  • by Geronimo Matteo, David C. Eickmeyer, Lauren M. Bradford, Matthew J. Meier, Andrew Williams, Tara Barton-Maclaren, J. Christopher Corton, Carole L. Yauk, Ella Atlas

  • April 20, 2026

Related Content

Correction: Regulatory actions of LH and follicle-stimulating hormone on breast cancer cells and mammary tumors in rats

MIT president: Why so many optimistic scientists are losing heart

Longitudinal predictor analysis of pain in breast cancer survivors on aromatase inhibitors—the PAC-WOMAN trial